An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Prostate cancer (PCa) is the second most common cancer diagnosis among men worldwide, with poor prognosis in its advanced stage. Treatment strategies have evolved, including the use of androgen receptor pathway inhibitors (ARPIs) and poly (ADP-ribose) …